Somapacitan

(Sogroya®)

Sogroya®

Drug updated on 11/15/2023

Dosage FormInjection (subcutaneous: 5 mg/1.5 mL (3.3mg/mL) or 10 mg/1.5 mL (6.7 mg/mL))
Drug ClassHuman growth hormone analogs
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for replacement of endogenous growth hormone in adults with growth hormone deficiency.

Product Monograph / Prescribing Information

Document TitleYearSource
Sogroya (somapacitan-beco) Prescribing Information.2021Novo Nordisk Inc., Plainsboro, NJ

Systematic Reviews / Meta-Analyses